Asia Myelodysplastic Syndrome (MDS) Registry
ConditionMyelodysplastic Syndromes (MDS)
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorBristol-Myers Squibb
About this trial
The purpose of this study is to provide a contemporary view and offer invaluable insights into the demographic profiles, clinical characteristics, treatments, and real-world outcomes of individuals with myelodysplastic syndromes (MDS) in Asia.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Aged at least 18 years at initial diagnosis of MDS
Diagnosed with MDS according to World Health Organization (WHO) 2008, WHO 2016, or WHO 2022 criteria between 1 January 2019 and 31 December 2022; and
Diagnosed with MDS within 100 days from the date of diagnostic bone marrow (BM) aspirate
Aged at least 18 years at initial diagnosis of MDS; and
Disqualifiers
None
Trial population
The registry will include adults who were/are newly diagnosed with myelodysplastic syndromes (MDS) in Asia (Singapore, South Korea and Taiwan).
Trial design
Design model
Cohort
Time perspective
Other
Treatments tested in this trial
Prescribed treatments for myelodysplastic syndromes (MDS)
DrugAccording to the product label
Treatment groups
500 Participants
are divided into 1 treatment groupGroup A: Group 11 intervention
Trial outcomes
Primary outcomes
1
Participant age
Time frame
Baseline2
Participant sex
Time frame
Baseline3
Participant race
Time frame
Baseline4
Participant weight
Time frame
BaselineSecondary outcomes
1
Initial treatment received following diagnosis
Time frame
Baseline2
Prior treatments and concomitant medications received
Time frame
Baseline3
Subsequent treatments received
Time frame
Up to 2-years4
Time from diagnosis to treatment initiation
Time frame
BaselineSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov